-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 14, the CDE official website showed that Qilu Pharmaceutical's nintedanib ethanesulfonate soft capsules were accepted for production as a generic Category 4 product
.
According to data from Minet.
com, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%, and it is expected to exceed 40 million yuan in 2021
.
At present, the only domestic manufacturers of this product are Boehringer Ingelheim and NBP Pharmaceuticals of CSPC
.
.
According to data from Minet.
com, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%, and it is expected to exceed 40 million yuan in 2021
.
At present, the only domestic manufacturers of this product are Boehringer Ingelheim and NBP Pharmaceuticals of CSPC
.
According to the data, nintedanib ethanesulfonate soft capsule is a multi-targeted tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which is the first approved in the world for the treatment of idiopathic pulmonary fibrosis (IPF) targeted drugs
.
.
Sales of nintedanib ethanesulfonate soft capsulesin Chinese urban physical pharmacies in recent years (unit: ten thousand yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
According to data from Minet, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%.
It is expected to exceed 40 million yuan in 2021, a year-on-year increase of 193.
73%
.
It is expected to exceed 40 million yuan in 2021, a year-on-year increase of 193.
73%
.
Source: One-click retrieval from Minet
At present, there are only two domestic manufacturers of nintedanib ethanesulfonate soft capsules, Boehringer Ingelheim and CSPC NBP Pharmaceuticals.
Among them, CSPC NBP Pharmaceuticals won the first imitation in March last year
.
In addition, Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical and Jiangsu Hansoh Pharmaceutical have submitted their marketing applications under the review and approval process under the category 4 generics
.
Among them, CSPC NBP Pharmaceuticals won the first imitation in March last year
.
In addition, Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical and Jiangsu Hansoh Pharmaceutical have submitted their marketing applications under the review and approval process under the category 4 generics
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, Qilu has 4 anti- tumor drugs , which will be approved for marketing under new classifications, which are deemed to have been passed.
comment .
Up to now, 6 anti-tumor drugs have submitted marketing applications for review and approval, including the Class 1 new drug Yiluoke Tablets .
comment .
Up to now, 6 anti-tumor drugs have submitted marketing applications for review and approval, including the Class 1 new drug Yiluoke Tablets .
On February 14, the CDE official website showed that Qilu Pharmaceutical's nintedanib ethanesulfonate soft capsules were accepted for production as a generic Category 4 product
.
According to data from Minet.
com, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%, and it is expected to exceed 40 million yuan in 2021
.
At present, the only domestic manufacturers of this product are Boehringer Ingelheim and NBP Pharmaceuticals of CSPC
.
.
According to data from Minet.
com, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%, and it is expected to exceed 40 million yuan in 2021
.
At present, the only domestic manufacturers of this product are Boehringer Ingelheim and NBP Pharmaceuticals of CSPC
.
According to the data, nintedanib ethanesulfonate soft capsule is a multi-targeted tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which is the first approved in the world for the treatment of idiopathic pulmonary fibrosis (IPF) targeted drugs
.
.
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan)
Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
According to data from Minet, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%.
It is expected to exceed 40 million yuan in 2021, a year-on-year increase of 193.
73%
.
It is expected to exceed 40 million yuan in 2021, a year-on-year increase of 193.
73%
.
Source: One-click retrieval from Minet
At present, there are only two domestic manufacturers of nintedanib ethanesulfonate soft capsules, Boehringer Ingelheim and CSPC NBP Pharmaceuticals.
Among them, CSPC NBP Pharmaceuticals won the first imitation in March last year
.
In addition, Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical and Jiangsu Hansoh Pharmaceutical have submitted their marketing applications under the review and approval process under the category 4 generics
.
Among them, CSPC NBP Pharmaceuticals won the first imitation in March last year
.
In addition, Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical and Jiangsu Hansoh Pharmaceutical have submitted their marketing applications under the review and approval process under the category 4 generics
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, Qilu has 4 anti- tumor drugs , which will be approved for marketing under new classifications, which are deemed to have been passed.
comment .
Up to now, 6 anti-tumor drugs have submitted marketing applications for review and approval, including the Class 1 new drug Yiluoke Tablets .
comment .
Up to now, 6 anti-tumor drugs have submitted marketing applications for review and approval, including the Class 1 new drug Yiluoke Tablets .
On February 14, the CDE official website showed that Qilu Pharmaceutical's nintedanib ethanesulfonate soft capsules were accepted for production as a generic Category 4 product
.
According to data from Minet.
com, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%, and it is expected to exceed 40 million yuan in 2021
.
At present, the only domestic manufacturers of this product are Boehringer Ingelheim and NBP Pharmaceuticals of CSPC
.
.
According to data from Minet.
com, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%, and it is expected to exceed 40 million yuan in 2021
.
At present, the only domestic manufacturers of this product are Boehringer Ingelheim and NBP Pharmaceuticals of CSPC
.
According to the data, nintedanib ethanesulfonate soft capsule is a multi-targeted tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which is the first approved in the world for the treatment of idiopathic pulmonary fibrosis (IPF) targeted drugs
.
.
Sales of nintedanib ethanesulfonate soft capsules in Chinese urban physical pharmacies in recent years (unit: ten thousand yuan)
pharmacy pharmacy Source: Minet.
com China's urban physical pharmacy terminal competition pattern
com China's urban physical pharmacy terminal competition pattern
According to data from Minet, the global sales of nintedanib in 2020 will exceed 2 billion US dollars, and the terminal sales growth of physical pharmacies in Chinese cities is astonishing, exceeding 600%.
It is expected to exceed 40 million yuan in 2021, a year-on-year increase of 193.
73%
.
It is expected to exceed 40 million yuan in 2021, a year-on-year increase of 193.
73%
.
Source: One-click retrieval from Minet
At present, there are only two domestic manufacturers of nintedanib ethanesulfonate soft capsules, Boehringer Ingelheim and CSPC NBP Pharmaceuticals.
Among them, CSPC NBP Pharmaceuticals won the first imitation in March last year
.
In addition, Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical and Jiangsu Hansoh Pharmaceutical have submitted their marketing applications under the review and approval process under the category 4 generics
.
enterprise enterprise enterpriseAmong them, CSPC NBP Pharmaceuticals won the first imitation in March last year
.
In addition, Sichuan Kelun Pharmaceutical Research Institute|Sichuan Kelun Pharmaceutical and Jiangsu Hansoh Pharmaceutical have submitted their marketing applications under the review and approval process under the category 4 generics
.
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, Qilu has 4 anti- tumor drugs , which will be approved for marketing under new classifications, which are deemed to have been passed.
comment .
Up to now, 6 anti-tumor drugs have submitted marketing applications for review and approval, including the Class 1 new drug Yiluoke Tablets .
tumor tumor tumor comment .
Up to now, 6 anti-tumor drugs have submitted marketing applications for review and approval, including the Class 1 new drug Yiluoke Tablets .
